SCHEMBL13531983

SCHEMBL13531983

COCC(=O)c1cc(Cl)c(Cl)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
ALDH1A1 P00352 5/20 0.41
TSHR P16473 3/20 0.41
HIF1A Q16665 2/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA13 Q8N1Q1 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8743285 0.81 TSHR (0.46) LMNAALDH1A1TSHRHPGDSMN1; SMN2
SCHEMBL28847068 0.79 ERCC5 (0.56) LMNAALDH1A1TSHRHIF1ACYP3A4
SCHEMBL31114507 0.79 ALDH1A1 (0.62) LMNAALDH1A1TSHRHIF1ACYP3A4
SCHEMBL24805156 0.77 L3MBTL1 (0.40) LMNAALDH1A1HPGDSMN1; SMN2CA12
SCHEMBL13887676 0.77 HPGD (0.60) LMNAALDH1A1HPGDSMN1; SMN2THRB
SCHEMBL27208789 0.74 ERCC5 (0.53) LMNAALDH1A1TSHRHPGDSMN1; SMN2
SCHEMBL19239519 0.73 RAB9A (0.40) LMNAALDH1A1CYP3A4HPGDSMN1; SMN2
SCHEMBL1280272 0.73 HPGD (0.57) ALDH1A1TSHRCYP3A4HPGD
SCHEMBL19328690 0.72 GAA (0.55) LMNAALDH1A1TSHRHIF1ACYP3A4
SCHEMBL8752440 0.72 HPGD (0.53) LMNAALDH1A1CYP3A4HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9101670-B2 Conjugates of an anti-TNF-α antibody NEKTAR THERAPEUTICS (US) 2015-08-11 US disclosed
US-20100021481-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY NEKTAR THERAPEUTICS (US) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021481-A1 CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY TNF, TNFRSF1A, TNFRSF9 LMNA 2141/4885ALDH1A1 2494/4885TSHR 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.